NAD+ in cellular energy
Electron transfer is the beginning of the story. Enzymes that consume NAD+ make the supply question much more interesting.
Electron transfer
The most persuasive thing about NAD+ is also the easiest thing to stretch too far. It acts as an electron-carrying coenzyme in cellular redox reactions. Redox is the chemical exchange of electrons. This gives NAD+ a direct role in metabolism, a much firmer starting point than a vague association with feeling lively.
I like the mechanical specificity of that role. A molecule has a job, reactions depend on it, and changing its availability can be investigated. Yet the review of human precursor trials describes inconsistent translation into clinical outcomes. The cellular job and the intervention question sit at different scales. Both are worth taking seriously.
A useful account also has to allow for location. NAD+ production and cycling are organised into cellular compartments and linked to metabolic signalling. That makes a single, undifferentiated idea of the body's energy supply feel rather crude to me. The location of a change can matter as much as its direction.
Enzymes that consume NAD+
NAD+ has another set of obligations. Sirtuins, PARPs and CD38/CD157 compete for the NAD+ pool. These are families of enzymes that use NAD+ in cellular processes; their names recur because an account of supply also needs an account of consumption.
That is the turn in the story I enjoy most. The question expands from how much NAD+ can be supplied to what happens to it after it arrives. The review of NAD+ metabolism during ageing connects its availability with cellular processes and disease susceptibility across model organisms and humans. It presents restoration as a candidate strategy. The word candidate is doing useful work.
The same review treats NAD+ as both a central coenzyme and a signalling substrate. I think that dual role deserves more space than it usually gets in a replenishment story. A cellular supply serves several processes, with consumption inside the cell helping to shape its availability.
CD38 in ageing mice
A particularly strong mechanistic example comes from mice lacking CD38. They were protected against the age-related fall in NAD+, with preservation of SIRT3 activity and improved mitochondrial function and metabolic health. The experiment connects an enzyme that consumes NAD+ with the availability of NAD+ and downstream function.
The experiment earns my admiration for its precision. Removing a particular enzyme gives the supply story a causal test, rather than merely observing that quantities change together. Its setting remains a mouse genetic experiment. It supports interest in NAD+ metabolism while leaving human supplementation as a separate question.
The later human evidence review adds a complication to the ageing premise itself: consistent observations of age-related NAD+ decline come from a limited number of human studies, and tissue-specific data remain sparse. That narrower human record deserves room alongside the striking mouse result.
NAD+ in cancer models
The cell benefiting from NAD+ matters too. In BRAF-inhibitor-resistant melanoma cell lines and mouse xenografts, resistant tumour cells increased the NAD+ biosynthetic enzyme NAMPT. Inhibiting NAMPT depleted NAD+ and ATP, and improved survival in the mice carrying the grafted tumours.
That experiment makes me distrust an indiscriminate goal of raising NAD+ everywhere. This is a concern about biological context, grounded in a tumour experiment. The study tested enzyme inhibition in cell lines and mice; it cannot calculate cancer risk from human supplementation. I am unwilling to turn that uncertainty into either a frightening prediction or a reassuring blanket statement. The biology is interesting precisely because the identity of the cell changes the question.